On January 4, 2024, C4 Therapeutics, Inc. closed the transaction. The company issued 5,567,928 shares at an issue price of $4.49 per share for the gross proceeds of $24,999,996.72.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.32 USD | +2.43% | -7.87% | +11.86% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
41.59 CNY | +2.59% | +8.59% | 2.34B | ||
6.32 USD | +2.43% | -7.87% | 423M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.86% | 423M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.